Brind.

Stifel lowered price targets on Revvity stock on September 4, 2025.

1 report, 1 independent Updated Sep 4

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Revvity Stifel

Keep exploring

The entities involved

Revvity
American biotech company
- Revvity and Codexis, both healthcare companies, are currently competing against each other for market share.Sun 08:23
- Dovish remarks made on September 3, 2025, eased market concerns regarding high interest rates, involving the FED and Jerome Powell.Sun 01:44
Stifel
American investment bank
- China and Stifel are currently top suppliers in the critical minerals market, with their market actions showing a preference for producers located outside of China.Mon 00:03
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.Sun 01:33

Related events

Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.Sep 1
Stifel lowered price target on Viking Holdings Ltd, citing European low-water risk. AQR Capital Management led by Cliff Asness tracks the company.Aug 29
Morgan Stanley maintained Equal Weight rating, Stifel lifted target price from $90 to $107, and TD Cowen stuck to its Hold rating for a company (implied to be Elastic).Sep 1

Coverage

Newest first; wire copies grouped

Sep 4StockStoryRevvity (RVTY) Stock Trades Down, Here Is Why Shares of life sciences company Revvity (NYSE:RVTY) fell 5.1% in the afternoon session after several analyst firms lowered their price targets on the sto